236 related articles for article (PubMed ID: 27494912)
1. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
[TBL] [Abstract][Full Text] [Related]
2. Optimization of polyene-azole combination therapy against aspergillosis using an in vitro pharmacokinetic-pharmacodynamic model.
Siopi M; Siafakas N; Vourli S; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3973-83. PubMed ID: 25896699
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
[TBL] [Abstract][Full Text] [Related]
4. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
5. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Seyedmousavi S; Meletiadis J; Melchers WJ; Rijs AJ; Mouton JW; Verweij PE
Antimicrob Agents Chemother; 2013 Feb; 57(2):796-803. PubMed ID: 23183435
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
[TBL] [Abstract][Full Text] [Related]
7. A New Marker of Echinocandin Activity in an
Meletiadis J; Siopi M; Tsakris A; Mouton JW; Pournaras S
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463527
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2013 Jan; 57(1):303-8. PubMed ID: 23114773
[TBL] [Abstract][Full Text] [Related]
9. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside.
Seyedmousavi S; Mouton JW; Melchers WJ; Brüggemann RJ; Verweij PE
Drug Resist Updat; 2014 Jul; 17(3):37-50. PubMed ID: 25066814
[TBL] [Abstract][Full Text] [Related]
10. Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an
Siopi M; Perlin DS; Arendrup MC; Pournaras S; Meletiadis J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495222
[TBL] [Abstract][Full Text] [Related]
11. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands.
van Ingen J; van der Lee HA; Rijs TA; Zoll J; Leenstra T; Melchers WJ; Verweij PE
J Antimicrob Chemother; 2015 Jan; 70(1):178-81. PubMed ID: 25301884
[TBL] [Abstract][Full Text] [Related]
12. In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions.
Fakhim H; Vaezi A; Dannaoui E; Sharma C; Mousavi B; Chowdhary A; Meis JF; Badali H
Diagn Microbiol Infect Dis; 2018 Jul; 91(3):266-268. PubMed ID: 29622284
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic analysis of voriconazole against Candida spp. and Aspergillus spp. in children, adolescents and adults by Monte Carlo simulation.
Xu G; Zhu L; Ge T; Liao S; Li N; Qi F
Int J Antimicrob Agents; 2016 Jun; 47(6):439-45. PubMed ID: 27179818
[TBL] [Abstract][Full Text] [Related]
15. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.
Lewis RE; Liao G; Hou J; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2011 Jun; 66(6):1324-31. PubMed ID: 21486855
[TBL] [Abstract][Full Text] [Related]
17. Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species.
Wiederhold NP; Locke JB; Daruwala P; Bartizal K
J Antimicrob Chemother; 2018 Nov; 73(11):3063-3067. PubMed ID: 30032217
[TBL] [Abstract][Full Text] [Related]
18. In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates.
Buil JB; Brüggemann RJM; Bedin Denardi L; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2020 Sep; 75(9):2582-2586. PubMed ID: 32516368
[TBL] [Abstract][Full Text] [Related]
19. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis.
Petraitis V; Petraitiene R; Hope WW; Meletiadis J; Mickiene D; Hughes JE; Cotton MP; Stergiopoulou T; Kasai M; Francesconi A; Schaufele RL; Sein T; Avila NA; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2009 Jun; 53(6):2382-91. PubMed ID: 19307368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
